Fundz Deep Dive
Everything you need to win Travere Therapeutics and CSL Vifor — in one platform.
Who to reach, what to say, and why now on Travere Therapeutics and CSL Vifor — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Travere Therapeutics and CSL Vifor — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Travere Therapeutics and CSL Vifor Launch FILSPARI for IgA Nephropathy Treatment in Switzerland
Oct 17, 2024•over 1 year ago
SwitzerlandBiotechnologyPharmaceuticalProduct Description
Travere Therapeutics and CSL Vifor have announced that FILSPARI has received temporary marketing authorization from Swissmedic for the treatment of adults with primary IgA nephropathy, offering a once daily, oral treatment option for patients in Switzerland.
Product Launch Insights
Based on market dataMarket expansion signals
New product launches often coincide with market expansion initiatives